European approval process for gallium-68 generator Eckert & Ziegler ended with success

European approval process for gallium-68 generator Eckert & Ziegler ended with success -

Radiopharma Eckert & Ziegler GmbH has received a recommendation from the European Agency drugs for approval of its pharmaceutical ⁶⁸ Ge / ⁶⁸ Ga generators. This achievement marks the conclusion of a comprehensive evaluation procedure and decentralized first gallium generator was approved for the clinical development of highly specific diagnostic agents. Approval for sale in the respective countries is planned in the next two months.

Gallium generators provide an inexpensive alternative to radiolabeling diagnostic probes using positron emission tomography (PET), an imaging process that can be used to determine whether the diseased tissue. The process is primarily used in the treatment of cancer. So far, fluorine-18 or carbon-11 isotopes PET has generally been used to radiolabel diagnostic probes; these radioisotopes are produced using cyclotrons which are capitally intensive large-scale facilities dedicated requiring million investment. However, gallium generator is about the size of a thermos and can come from a lot less money, reducing costs and increasing flexibility in nuclear medicine clinics.

Once it was approved, Eckert & Ziegler will also submit its documents to the US Food and Drug Administration (FDA), the establishment of a Drug Master File with the agency. This will allow parties interested in developing new drugs to consult the file and use the generator in clinical trials of drugs and other parameters.

Dr. André Heβ, member of the Board of Eckert & Ziegler AG and head of Radiopharma segment, said, "We are proud to have got the ball rolling on the first approval of the world a pharmaceutical product ⁶⁸ Ge / ⁶⁸ Ga generator. We also would like to encourage the departments of research and academic development in the global pharmaceutical industry to introduce more substances which may be radiolabeled with Ga-68 in clinical development. approaches 'Theranostic' that combine the diagnosis using Ga -68 PET with treatment using Yttrium-0, coupled using the same carrier molecule, are also very promising. "

TAS-102 Phase III study for metastatic colorectal cancer showed improved survival

TAS-102 Phase III study for metastatic colorectal cancer showed improved survival -

ESMO 16th World Congress on the GI gastrointestinal cancer

The new TAS-102 combination agent is able to improve overall survival compared to placebo in patients with metastatic colorectal cancer refractory to standard treatments, the researchers said global ESMO 16 Congress gastrointestinal cancer intestinal Barcelona.

"About 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard treatments," said Takayuki Yoshino of the Hospital East National Cancer Center Chiba, Japan, the lead author of the Phase III trial RESORT. "The study shows that RESORT TAS-102 improves overall survival in these patients compared to placebo. I believe that this agent will become one of the standards of care in the context refractory metastatic colorectal cancer in Japan and the world."

TAS-102 is a novel anti-tumor nucleoside consists of trifluridine agent (FTD) and tipiracil hydrochloride (TPI). DFT is the active component of TAS-102 and is directly incorporated into the DNA of cancer, leading to dysfunction of DNA. However, where FTD is taken orally, it is largely degraded to an inactive form. TPI prevents the degradation of FTD. This mechanism of action is different from that fluoropyrimidine, oxaliplatin, and irinotecan.

The Phase II trial of TAS-102 had found an overall survival benefit in Japanese patients with refractory colorectal cancer metastases to fluoropyrimidine 5-fluorouracil (5-FU), irinotecan and oxaliplatin.

The current study was a RESORT global phase III trial conducted in 13 countries at 114 centers. The patients had refractory metastatic colorectal cancer to all standard therapies, including fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and cetuximab or panitumumab in patients with KRAS wild type tumors. The patients were randomized 2: 1 to TAS-102 (534 patients) or placebo (266 patients). The primary endpoint was overall survival

The researchers found that TAS-102 prolonged overall survival compared to placebo (hazard ratio 0.68) :. Median overall survival was 7.1 months for TAS-102 and 5.3 months for the placebo group. TAS-102 also improved progression-free survival compared to placebo (hazard ratio 0.48), which was a secondary endpoint. Yoshino said. "We found a statistically significant difference in overall survival and progression-free and clinically significant improvement"

"TAS-102 has a soft safety profile and the most common side effect is hematologic toxicity including neutropenia. patients with refractory to standard therapies of metastatic colorectal cancer now have a strong treatment option. "

Commenting on these data, ESMO spokesperson Jean Yves Douillard, Professor of oncology medical Institute of Meteorology Canc-West (ICO) Ren- Gauducheau, Saint-Herblain, France, said: "the trial of TAS-102 phase III is a comprehensive study and confirms the results of the study Phase II in Japanese patients, whose response to fluoropyrimidine is slightly different from patients in Europe and the United States. It is good to know that the magnitude of the benefit shown in smaller phase II trial is confirmed in Phase III testing more and that the results are applicable to Asians and Caucasians alike. "

TAS-102 is a combination of two components. tipiracil hydrochloride (ITP) prevents degradation of trifluridine (FTD) and also has an angiogenic activity. "This is probably why TAS-102 is effective in fluoropyrimidine 5-fluorouracil classic (5-FU) resistant patients. The drug is very promising, the tolerance is good and is manageable with supportive care."

Douillard concluded "in RESORT, TAS-102 was tested in patients who received any type of chemotherapy available for colorectal cancer, I'd probably move this drug in an earlier line of treatment and I would also combine either irinotecan or oxaliplatin with .. "

Researchers are developing a new way to identify potential therapeutic targets for melanoma resistant to drugs

Researchers are developing a new way to identify potential therapeutic targets for melanoma resistant to drugs -

Their analysis process will identify potential new therapeutic targets

researchers Moffitt Cancer Center developed a new way to identify possible therapeutic targets for patients with melanoma drug resistant. It involves the use of the liquid mass spectrometry control of the reaction multiple chromatography to measure biomarkers or molecules in the blood and tissue that indicates cancer is present. These measures may help researchers determine whether a patient is responding to treatment.

Scientists have made significant progress identifying important molecules that contribute to melanoma growth and metastasis, such as BRAF and MEK proteins. Therapeutic agents that target these molecules have shown promising results in the clinic, and many patients have significant reductions in tumor growth and tumor burden.

"Although drugs targeted therapy, such as inhibitors of BRAF and MEK, have been associated with impressive responses in melanoma patients, most patients eventually fail therapy," said Keiran Smalley, Ph.D., associate member of the cancer biology and Evolution program at Moffitt.

tumors can develop different mechanisms of resistance and adapt targeted agents in order to survive and continue to grow. "It is likely that the long-term management of melanoma patients will require combinations of drugs, "said Smalley.

the molecular changes that lead to drug resistance varies between patients and each tumor. the identification these molecular changes with current scientific approaches is difficult, expensive and time consuming.

Smalley the team, in collaboration with the laboratory of John Koomen, Ph.D. in chemical biology and Moffitt molecular medicine program, developed a multiple liquid chromatography assay reaction monitoring mass spectrometry to analyze more than 80 proteins known to be important in melanoma progression and resistance to targeted therapies. They showed that melanoma cells that are resistant to drugs that target MEK have alterations in a number of different cell signaling pathways. The results of this kind will enable the development of new treatment strategies.

The researchers plan to accelerate the identification of proteins involved in resistance of melanoma by use of multiple chromatography reaction monitoring mass spectrometry liquid medications. The platform for the simultaneous detection of multiple proteins in small amounts of tissue samples. This also results in highly reproducible data that can be easily validated between different laboratories.

everolimus drug fails to improve overall survival in patients with advanced liver cancer

everolimus drug fails to improve overall survival in patients with advanced liver cancer -

Despite strong preclinical data, drug everolimus has failed to improve overall survival in patients with advanced liver cancer, compared with placebo, according to a study published in the July 2 issue of JAMA

patients with advanced hepatocellular carcinoma. (HCC, a type of liver cancer) have a median overall survival of less than one year, largely because of the lack of effective treatments. The drug sorafenib is the only systemic therapy shown to significantly improve overall survival in advanced HCC; but its benefits are often transitory and modest, and the disease eventually progresses. In preclinical models, everolimus prevented tumor progression and improved survival, according to background information in the article.

Andrew X. Zhu, MD, Ph.D., of the Hospital Cancer Center at Massachusetts General, Harvard Medical School, Boston, and colleagues randomly assigned 546 adults with advanced HCC whose disease progression during or following sorafenib or sorafenib were intolerant to receive everolimus (n = 362) or placebo (n = 184), both given in combination with best supportive care and continued until progression of the disease or intolerable toxicity. In this phase 3 study, patients were recruited from 17 countries between May 2010 and March 2012.

The researchers found no significant difference in overall survival between the two groups, there were 303 deaths ( 83.7 percent) in the everolimus group and 151 deaths (82.1 percent) in the placebo group. The median overall survival was 7.6 months with everolimus, 7.3 months with placebo. disease control rate (percentage of patients with a better overall response of the complete or partial response or stable disease) was 56.1 percent (everolimus) and 45.1 percent (placebo).

"The results of [this study, EVOLVE-1] extend the list of failed phase 3 study in advanced HCC, highlighting the challenge of developing effective therapies for this cancer," the authors write.

the researchers note that the EVOLVE-and the other phase 3 studies failed provided several important lessons, including that it is difficult to assess the effectiveness of Phase 2 testing signals; endpoints substitution such as time to progression, progression free survival and response rate incompatible predict overall survival in Phase 3 trials, and clinical and biological heterogeneity likely affects the performance of targeted therapies in HCC "in the. lack of predictive biomarkers well characterized and validated, the targeted agents are likely to continue to have a high risk of failure if the phase 3 trials are performed in non-selected populations. "

New hope for women with breast cancer at an early stage

New hope for women with breast cancer at an early stage -

Women with early stage breast cancer can now receive treatment radiation a dose along with lumpectomy surgery, eliminating the need to return to the hospital every day for up to six weeks to submit surgical radiation treatment.

relatively new treatment option available to Rush, intraoperative radiation therapy (IORT), delivers an accurate dose of concentrated radiation to the tumor site immediately after surgical removal of the cancer.

After breast cancer is removed, a device similar to a catheter with a balloon on the end is inserted into the lumpectomy cavity. The balloon is inflated with saline and the quays radiation source precisely in the catheter for delivering radiation into the surrounding breast tissue the cavity where the tumor has been removed, while preventing the radiation to adjacent organs. At the end of radiation treatment, the balloon is deflated and easily removed and the cavity is closed.

"We are currently IORT for women with breast cancer in early stage. However, there are exciting research on the use of this modality for other types of patients, including those who breast cancer recurrences or those subject to a mastectomy nipple preserving "said Dr. Katherine Kopkash, Assistant Professor of surgery, Rush University Medical Center.

generally breast cancer treated with lumpectomy require radiotherapy after surgery to ensure the lowest risk of recurrence. Standard radiation therapy requires patients to return after recovery from surgery to start daily radiation treatment to the entire chest five days a week, for a total of three to six weeks.

"As the time of surgery with intraoperative radiotherapy recovery is the same as surgeries performed without IORT, the total time patients spent in the hospital receiving treatment for breast cancer decreased significantly. This allows patients to return to their lives faster by potentially reducing the need for new therapies and improve their quality of life, "said Kopkash.

IORT may be a treatment option especially important for women who live in rural areas and have to travel long distances for treatment against breast cancer, "said Kopkash." the distance creates a real barrier to women returning repeatedly to the treatment of radiation . Unfortunately, these women often choose to have a mastectomy to avoid the need for radiation. "

Currently IORT is not yet widely available in the United States but has been used in Europe since the 190s began being used more widely in the United States there are about ten years and has been studied in clinical trials. Rush began to deal with his unit of IORT in February 2014 more than 15 women have been treated with IORT by Kopkash and colleagues at Rush.

cancer patients Rush to the breast are able to be seen by a medical oncologist, a radiation oncologist and surgeon at the same time in Coleman Foundation Comprehensive cancer Clinic. These cancer doctors work in teams to present a well -defined diagnosis and plan treatment for each patient.

According to the American cancer Society, approximately 40,000 women die each year of breast cancer and 232.670 new cases will be diagnosed in women each year.

Poor nutrition, the cause of health disparities in fetal growth and size of newborns worldwide

Poor nutrition, the cause of health disparities in fetal growth and size of newborns worldwide -

poor nutrition and health , not racial or ethnic origin, cause most of the large existing disparities in fetal growth and size of the newborn

the growth of babies in the womb and birth size, in particular their length, are strikingly similar worldwide -. when babies are born to the health, well-educated and well-nourished mothers

This is the conclusion of an international historical, intergrowth-21, conducted by researchers from the University of Oxford, who involved nearly 60,000 pregnancies in eight urban areas defined in Brazil, China, India, Italy, Kenya, Oman, the United Kingdom and the USA.

worldwide there are large differences in the average size of babies at birth. This has important implications for the future health, such as small for gestational age babies who are already undernourished at birth often face severe short- and consequences on long-term health.

There has already been suggested that the "race" and "ethnicity" are largely responsible for differences in the size of babies born in different populations and countries. These new results show that race and ethnicity are the main factors. What matters most is education, health and nutritional status of mothers and care during pregnancy.

The researchers performed ultrasound for early pregnancy to delivery to measure bone growth of babies in the womb, using identical methods in all countries and the same ultrasound machines provided by Philips Healthcare. They also measured the length and head circumference of all babies at birth.

They showed that if education, maternal health and nutritional status and treatment during pregnancy are also good, babies have equal chances of healthy growth and future healthy uterus .

researchers report their findings in The Lancet, diabetes and endocrinology. They were funded by the Bill & Melinda Gates Foundation.

"Currently, we are not all equal at birth. But we can be, says lead author Professor José Villar of the Nuffield Department of Obstetrics and Gynecology, University of Oxford." We can create a similar start for all by ensuring that mothers are well educated and fed, by treating the infection and providing adequate prenatal care.

'do not say we can not do anything. do not that women in parts of the world have small children because they are predestined to do so. It is simply not true.

Highlights

• the study involved nearly 60,000 pregnancies in eight urban areas defined in Brazil, China, India, Italy, Kenya, Oman, the United Kingdom and the United States
• bone growth of babies in the womb and their length and head circumference at birth are strikingly similar worldwide -. when babies are born to educated mothers, healthy and well fed.
• overall, not more than 4% of the total difference in fetal growth and birth size could be attributed to differences between the eight populations studied.
• Improving education, health and nutrition of mothers will boost the health of their babies throughout life in the next generation.
• results are in agreement with the study of previous WHO, using the same methodology from birth to 5 years.

in 2010, an estimated 32.4 million children have been born already undernourished in countries with low and middle income, representing 27% of all live births worldwide . This is closely associated with illness and death in infancy and childhood. Small birth size has an impact on the health of adults too, with increased risk of diabetes, hypertension and cardiovascular disease. Smaller babies also significant costs to health services and a significant economic burden on society as a whole.

Part of the problem to begin to improve outcomes of pregnancy is fetal growth and size of the newborn are currently being evaluated in clinical worldwide using at least 100 different growth curves . In other words, there are no international standards at present for the fetus and the newborn, while such standards exist for infants and children.

"It's very confusing for doctors and mothers and has no biological meaning. How a fetus or a newborn may be considered low in a clinic or hospital and treated accordingly, only for the mother to go to another city or country, and being told that her baby is developing normally, "said Professor Stephen Kennedy, University of Oxford, one of the main authors of the paper

the ultimate goal of the intergrowth-21 study is to build international standards describing optimal growth of a baby in uterus and as a newborn -. standards to reflect how a baby should develop when mothers have adequate health, nutrition and socioeconomic status.

researchers have adopted the same approach adopted by the multicenter study on the WHO growth reference for infants and children healthy, which established international growth standards from birth to 5 age years that are now used in over 140 countries worldwide.

The intergrowth-21 results are fully consistent with the existing WHO standard infant. The average length at birth of newborns in the intergrowth-21 study was 49.4 -. 1.9 cm, 1.9 cm against 49.5 in the study of infant WHO

From now on international standards can be used worldwide to make judgments on growth and the size of the design for 5 years. "Just think, if your cholesterol or your blood pressure is high, they are high, no matter where you live. Why should not the same to growth? Villar said the professor

Professor Pang Ruyan, from Peking University, China, one of the lead investigators of the study, said :. "The 21st-intergrowth results are fully consistent with the WHO child growth standards for infants and for existing. Having international standards of optimum growth from conception to 5 years that everyone in the world can use means it will now possible to assess the improvement of health and nutrition using the same criteria.

Professor Zulfiqar Bhutta of Aga Khan University in Karachi, Pakistan and the Hospital for Sick Children, Toronto, Canada who is the chairman of the board of this global research team, said "the fact that when mothers are healthy, babies grow in the womb in a very similar the world over is an extremely positive message hope for all women and their families, but there is a challenge as well There are implications for how we think about public health:.. This is about the chances of health and life of future citizens around the world. All those responsible for health care should consider offering the best maternal and child health.

Oncolytics complete patient enrollment in Study II in metastatic pancreatic cancer Phase

Oncolytics complete patient enrollment in Study II in metastatic pancreatic cancer Phase -

Oncolytics Biotech Inc. ( "Oncolytics") (TSX: ONC, NASDAQ: ONCY) announced today the completion of patient enrollment in a study carboplatin, paclitaxel plus REOLYSIN ^® against carboplatin and paclitaxel alone in the first-line treatment of patients recurrent or metastatic cancer of the pancreas (OSU-10045) in two randomized phase II arm. The principal investigator is Tanios Bekaii-Saab, MD, associate professor and chief of gastrointestinal oncology section of the Comprehensive Cancer Center at Ohio State University - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC of - James) . The trial is sponsored by the National Cancer Institute of the USA (NCI) through an agreement on clinical trials between the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis and Oncolytics. Oncolytics provide clinical supplies of REOLYSIN for the study.

"This is the second randomized trial using REOLYSIN to complete registration," said Dr. Brad Thompson, President and CEO of Oncolytics. "This study is important given the relatively limited treatment options and generally a poor prognosis for patients with pancreatic cancer, which often are not diagnosed until the later stages of the disease."

the study is an open-label, multi-institution, phase II two-arm randomized study of patients with metastatic pancreatic cancer. patients were randomized to receive either carboplatin, paclitaxel plus REOLYSIN ( arm a) or carboplatin and paclitaxel alone (arm B). patients in both arms received treatment every three weeks (21 day cycles) and standard intravenous doses of paclitaxel and carboplatin on day one only. in arm a, the patients also received intravenous REOLYSIN at a dose of 3x10 ¹⁰ TCID ₅₀ the one to five days. assessment of tumor response was performed by CT (TDM) and conducted every eight weeks. Patients who progress on carboplatin and paclitaxel (Arm B) had added REOLYSIN. If patients have significant toxicity related to carboplatin and / or paclitaxel they may continue with single agent REOLYSIN.

The primary objective of the trial is to evaluate the improvement of progression-free survival with REOLYSIN, carboplatin and paclitaxel versus carboplatin and paclitaxel alone in patients with pancreatic cancer metastatic. The primary endpoint is progression-free survival in both arms. Secondary endpoints include overall response rate and overall survival. The study included 70 evaluable patients in test centers across the United States.

As a sponsor of the study, the NCI is responsible for tracking patients and collect and compile all patient data. Once completed, the data will be analyzed and provided for Oncolytics.

Bekaii-Saab, principal investigator of the clinical study, has no financial interest in Oncolytics, REOLYSIN the manufacturer of the investigational product.

patients with colon cancer with high levels of vitamin D are more likely to survive the disease

patients with colon cancer with high levels of vitamin D are more likely to survive the disease -

patients with bowel cancer with high levels vitamin D in their blood are more likely to survive the disease, a study shows.

patients with the highest levels of vitamin D had half the risk of dying compared to those with the lowest levels, the results indicate.

study is the first to correlate the total blood levels of vitamin D in patients with cancer of the intestine after diagnosis - including one produced after exposure to sunlight and that obtained from dietary sources -. with their long-term survival prospects

The University of Edinburgh team tested blood samples from nearly 1,0 patients after surgery for bowel cancer.

the biggest benefit of vitamin D was observed in patients with stage 2 disease, in which the tumor can be quite large, but the cancer has not yet reached.

researchers found that three-quarters of patients with vitamin D levels higher were alive at the end of five years, compared to less than two thirds of those with levels lower.

results show that vitamin D is associated with a much better chance of survival in cancer, although the nature of this relationship is not clear from this study.

authors of the study are intended to set up a clinical trial to test whether taking vitamin D tablets in combination with chemotherapy can improve bowel cancer survival rates.

levels of vitamin D measurement in patients with bowel cancer could also provide a useful indication of the prognosis, scientists say.

Professor Malcolm Dunlop, the Human Genetics Unit of the Medical Research Council at the University of Edinburgh, said. "Our results are promising, but it is important to note that this is an observational study we we need carefully designed randomized clinical trials before we can confirm whether taking vitamin D supplements offer a survival advantage for patients with bowel cancer. "

Penn receives $ 8 million grant from the NCI to study the effects of PDT

Penn receives $ 8 million grant from the NCI to study the effects of PDT -

Perelman School Researchers at the Medical University of Pennsylvania in collaboration with Roswell Park cancer Institute received $ 8 million grant from the National cancer Institute (NCI) to study the effects of photodynamic light therapy (PDT) in patients with malignant pleural mesothelioma, a rare cancer , aggressive and deadly that most often occurs in the lining of the lungs and is caused almost exclusively by exposure to asbestos. The grant will fund clinical trials and other studies examining the effects of PDT on the patient's response to the shelter, the tumor cell itself, and blood vessels surrounding the tumor.

Approximately 3,000 new cases of mesothelioma are diagnosed each year in the US, with numbers expected to rise worldwide due to uncontrolled exposure to asbestos.

"Mesothelioma is a cancer for which there is currently little or no hope of recovery," said Eli Glatstein, MD, principal investigator of the grant of the proposed program and professor and vice president radiation oncology and a member of pleural mesothelioma and Penn program, one of the world's leading centers for research and treatment of mesothelioma. "This trial is an important step in understanding the combination treatment modalities that offer patients the best hope for the survival and prolonged remission. "

The study, which plans to enroll 102 patients over four years, will administer Photofrin, a photosensitizing agent that makes cancer cells more susceptible to dying from light therapy, the trial participants 24 hours before surgery. Patients will be a radical pleurectomy, removal of the pleura or lining of the lung and tumor cells contain. They will then be randomized into two arms: half will receive intraoperative PDT by intense laser inserted into the chest cavity during surgery and postoperative chemotherapy standard; and that only half will receive a post-operative chemotherapy. Photofrin absorbs the laser light and produces an active form of oxygen that can destroy microscopic residual cancer cells left after surgery. Radical pleurectomie allows mesothelioma patients to keep their lungs and is associated with better postoperative quality of life and improved survival compared to other cities definitive mesothelioma surgeries.

"PDT has been a part of our treatment plan with Lung-sparing surgery for many years, but a randomized clinical trial, as is still needed to prove its effectiveness," said Glatstein.

PDT is known to kill cancer cells, but researchers are also trying to understand the patient's immune response, the microenvironment of the tumor and the blood vessels in and around the tumor in three additional studies funded under the grant.

the second project will examine the process by which PDT works to destroy tumor cells and look where a drug agent -a or other treatment that may increase its effects.

the third project will investigate whether certain channels awakened during surgery can play a key role in inflammation and cell growth and contribute to treatment failure in some way, and whether inhibition of these pathways will allow improve the effectiveness of intraoperative PDT.

Finally, the team will study the tumor vasculature in the following patients PDT and assess changes in the vascular environment as a result of intraoperative PDT and the modulation potential to improve the efficacy of treatment.

"This trial will help us understand how PDT works in the body and what we can be able to do in the future to improve the body's response to therapy," said Glatstein .

Dmitry Medvedev presents national first "Industry" price Biocad

Dmitry Medvedev presents national first "Industry" price Biocad -

On July 9, Prime Minister of the Russian Federation Dmitry Medvedev presented the first national "Industry" price from Russia to Russia Biocad a biopharmaceutical company. The company develops a unique project called MabNext. Under the MabNext Biocad project is developing a number of innovative drugs based on monoclonal antibodies for the treatment of cancer and autoimmune diseases. The ceremony took place at the International Exhibition "INNOPROM 2014" in Ekaterinburg.

According to the Russian Ministry of Health, over the last 12 years, the number of new cases of malignant tumors increased by 11%. The constantly increasing number of cancer patients is a global trend. According to the International Agency for Research on Cancer, over the next 20 years, the number of new cancer patients in the world will rise to 22 million cases per year. Consequently, Russia and the rest of the world are so desperate for new effective drugs that will help overcome serious diseases and save millions of lives.

Biocad develops a wide range of innovative products based on monoclonal antibodies for the treatment of diseases such as breast cancer, colorectal cancer, lung cancer, melanoma, multiple sclerosis, rheumatoid arthritis and psoriasis.

"Today, the country is undergoing fundamental changes with regard to the availability of modern medicines for its people. Thanks to the support of the Ministry of Industry and Trade, Ministry of Health, Ministry economic development, the Russian pharmaceutical companies create a strong technological basis for the production of innovative products and compete successfully in the global pharmaceutical market. of course, our foreign colleagues are not happy with this. However, we can now provide innovative medicines which have no analogues in the world. MabNext the project is a shining example of this, "said Dmitriy Morozov, CEO of Biocad.

The main advantage of monoclonal antibody-based products is that they affect cells or selected molecules, in other words, these therapies are targeted. Only the relevant targets are neutralized without affecting healthy cells.

Biocad has over 10 of these innovative products based on monoclonal antibodies at various stages of development. One of the most notable is an antibody specific for interleukin 17. Clinical trials of this drug will begin in 2014. The drug has no analogues in the market and its characteristics are superior to anti-IL17 antibodies in the process of development by foreign companies. This product has huge potential as regards the treatment of socially significant diseases such as rheumatoid arthritis and psoriasis

If we talk about cancer -. The company is at the stage of development of original products based on monoclonal antibodies against targets such as PD-1, Ang-2 HER3 and others. PD-1 antibody to increase the patient's immune system's ability to recognize and destroy tumor cells.